GlassScriptPhysician profile
Ulyana Trytko
NPI 1831648344
$5,196.90
in general payments reported to CMS, 2019-2025
29 companies · $681 in 2025
The $681 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $192 · 2021: $801 · 2022: $1,036 · 2023: $1,083 · 2024: $1,220 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.53 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,411.94 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $505.36 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $463.81 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Csl Behring | $401.44 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Glaxosmithkline, LLC. | $242.39 | 2020-2023 | Arexvy, Nucala |
| Amgen INC. | $233.11 | 2022-2024 | Tezspire |
| Abbvie INC. | $228.96 | 2022-2024 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $216.82 | 2021-2024 | Dupixent |
| Pfizer INC. | $212.43 | 2022-2024 | |
| Optinose US, INC. | $164.93 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $147.02 | 2019-2021 | |
| Genentech USA, INC. | $133.66 | 2020-2024 | Xolair |
| Covis Pharma Gmbh | $103.13 | 2021-2022 | |
| Incyte Corporation | $100.39 | 2021-2024 | Opzelura |
| Kaleo, INC. | $99.92 | 2021-2023 | Auvi-Q |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $93.24 | 2025 | Neffy |
| Alk-Abello, INC | $61.66 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $60.91 | 2021-2023 | Orladeyo |
| Leo Pharma INC. | $57.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.80 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $33.00 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $30.09 | 2020-2021 | |
| Blueprint Medicines Corporation | $29.14 | 2022 | |
| Merck Sharp & Dohme LLC | $16.27 | 2023 | |
| Horizon Therapeutics Plc | $15.33 | 2022 | |
| Pharming Healthcare, INC. | $14.55 | 2022 | |
| Octapharma USA, INC. | $14.44 | 2023 | Panzyga |
| Phadia US INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulyana Trytko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.